Boundless Bio
BOLDBOLD · Stock Price
Historical price data
Overview
Boundless Bio is a pioneer in oncology, founded to address the unmet need in cancers driven by oncogene amplification, which affect over 25% of all cancer patients. The company has established itself as the leader in the field of extrachromosomal DNA (ecDNA), leveraging its proprietary platform to develop first-in-class ecDNA-directed therapies (ecDTx). With a Phase 1 asset and a seasoned leadership team, its strategy is to validate a new therapeutic paradigm that could improve outcomes for patients with some of the most aggressive and treatment-resistant cancers.
Technology Platform
Proprietary platform focused on targeting extrachromosomal DNA (ecDNA), a circular genetic driver of high-level oncogene amplification, tumor heterogeneity, and therapy resistance in cancer cells.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| BBI-355 + Erlotinib + Futibatinib + BBI-825 | Triple Negative Breast Cancer (TNBC) | Phase 1 | |
| BBI-825 | Solid Tumor | Phase 1 | |
| BBI-940 + Fulvestrant | Breast Cancer | Phase 1 |
Funding History
8Opportunities
Risk Factors
Competitive Landscape
Boundless Bio is the first-mover in ecDNA-targeted therapies, but faces potential competition from emerging biotechs and academics. Indirectly, it competes with all therapies targeting amplified oncogenes (e.g., TKIs, ADCs), but aims to differentiate by targeting the root cause of resistance.
Company Timeline
Founded in San Diego, United States
Series A: $105.0M
IPO — $185.0M
Series F: $100.0M